瘤微环境中的衰老免疫细胞:对癌症免疫疗法耐药性的新兴见解
Duolun Gao1, Peiyan Kan1, Yanjie He2
1Department of Gastroenterology, Engineering Research Center of Ministry of Education for Minimally Invasive Gastrointestinal Endoscopic Techniques, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
免疫细胞衰老通过创造一种免疫抑制瘤微环境,损害了抗瘤免疫力和免疫疗法的有效性. 与免疫疗法一起向衰老细胞可能会提高癌症治疗的有效性.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
背景情况:
- 癌症是一个全球性的健康挑战,传统的治疗方法面临诸如副作用和复发等局限性.
- 瘤免疫疗法,包括免疫检查点抑制剂和CAR T细胞疗法,提供了一个有前途的方法,但面临着挑战.
- 瘤微环境 (TME) 通常具有免疫抑制作用,阻碍有效的抗瘤免疫反应.
研究的目的:
- 审查免疫细胞衰老在建立免疫抑制性TME的关键作用.
- 探索免疫细胞衰老如何促进对当前免疫疗法的抵抗.
- 讨论新的治疗策略,将免疫疗法与针对衰老的干预措施结合起来.
主要方法:
- 文献综述专注于免疫细胞衰老,TME和癌症免疫治疗之间的相互作用.
- 分析衰老免疫细胞抑制抗瘤免疫力的机制.
- 对新兴的老化向疗法的证据综合.
主要成果:
- 衰老的免疫细胞表现出功能受损,抑制检查点分子表达增加,以及促炎性细胞因子分泌.
- 衰老免疫细胞的这些特征有助于抑制TME,降低抗瘤免疫力.
- 免疫细胞衰老被认为是免疫疗法耐药性的关键因素.
结论:
- 免疫细胞衰老是有效的癌症免疫疗法的重要障碍.
- 将免疫疗法与向衰老细胞的干预措施相结合,为克服治疗耐药性提供了一个有希望的策略.
- 对针对衰老的治疗方法的进一步研究可能会导致更有效的癌症治疗方法.
更多相关视频
08:56Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells
Published on: July 12, 2022
09:04Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
相关概念视频
The Tumor Microenvironment
Treatment Resistant Cancers
Tumor Immunotherapy
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Replicative Cell Senescence
